-+ 0.00%
-+ 0.00%
-+ 0.00%

*Candel Therapeutics Sees Funding Initiation of Potentially Registrational Phase 3 Trial of CAN-2409 in NSCLC and Other Planned Ops Into 1Q 2027 >CADL

Dow Jones·11/13/2025 13:26:00

Please log in to view news